Patents Assigned to Genentech
  • Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer
    Patent number: 11891437
    Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: February 6, 2024
    Assignee: Genentech, Inc.
    Inventors: Amin Famili, Germaine Fuh, Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal
  • PREDICTING DISEASE PROGRESSION BASED ON DIGITAL-PATHOLOGY AND GENE-EXPRESSION DATA
    Publication number: 20240038393
    Abstract: In some embodiments, a current state of a medical condition or a progression of the medical condition is predicted by processing one or more digital pathology images and expression levels of genes using a machine-learning model. In some embodiments, one or more predicted gene-expression levels are generated by processing a data set corresponding to one or more digital pathology images using a machine-learning model. In some embodiments, one or more predicted digital pathology metrics are generated by processing a data set that corresponds to expression levels of a set of genes using a machine-learning model.
    Type: Application
    Filed: August 14, 2023
    Publication date: February 1, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Xiao Li, Marius Rene Garmhausen, Gunther Jansen, Teresa Melanie Karrer
  • COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
    Publication number: 20240033351
    Abstract: The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.
    Type: Application
    Filed: October 10, 2022
    Publication date: February 1, 2024
    Applicant: Genentech, Inc.
    Inventor: Paul BRUNETTA
  • Anti-Jagged Antibodies and Methods of Use
    Publication number: 20240034805
    Abstract: The invention provides anti-Jagged antibodies and methods of using the same.
    Type: Application
    Filed: May 22, 2023
    Publication date: February 1, 2024
    Applicant: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS
    Publication number: 20240034739
    Abstract: Processes are provided herein for the preparation of a bicyclic ketone compound of formula (I), or a stereoisomer thereof: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and n are as defined herein; and compounds prepared by these processes.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 1, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Allen Yu HONG, Nicholas WONG, Sean M. KELLY, Lauren Elizabeth SIROIS, Sara SCHWEGLER, Xin LINGHU, Francis GOSSELIN, Katarzyna Aleksandra PIECHOWICZ, Carmela MOLINARO, Dennis WETZL
  • METHOD FOR TREATING PNEUMONIA, INCLUDING COVID-19 PNEUMONIA, WITH AN IL6 ANTAGONIST
    Publication number: 20240025991
    Abstract: The application describes a method of treating pneumonia (e.g. COVID-19 pneumonia) in a patient comprising administering a weight-based intravenous dose of tocilizumab to the patient, wherein the weight-based dose is 8 mg/kg of tocilizumab. It also describes a method of treating pneumonia in a patient comprising administering an IL6 antagonist (e.g. an IL6 receptor antibody such as tocilizumab) to the patient in an amount effective to achieve a greater improvement in clinical outcome than standard of care (SOC) as measured on an ordinal scale of clinical status.
    Type: Application
    Filed: March 19, 2021
    Publication date: January 25, 2024
    Applicant: Genentech, Inc.
    Inventors: Min Bao, Larry Wilse Tsai
  • ANTIBODIES AND METHODS OF USE
    Publication number: 20240026033
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: March 31, 2023
    Publication date: January 25, 2024
    Applicant: Genentech, Inc.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • CD8+ t cell based immunosuppressive tumor microenvironment detection method
    Patent number: 11881286
    Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 23, 2024
    Assignee: GENENTECH, INC.
    Inventors: Akshata Ramrao Udyavar, Yulei Wang, Cleopatra Kozlowski
  • ANTI-CD8 ANTIBODIES AND USES THEREOF
    Publication number: 20240018241
    Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.
    Type: Application
    Filed: June 30, 2023
    Publication date: January 18, 2024
    Applicant: Genentech, Inc.
    Inventors: Yvonne M. CHEN, Eugene Yu-Chuan CHIANG, Jane Louise GROGAN, Simon-Peter WILLIAMS, Matthew Lawrence ALBERT
  • PROCESS FOR THE PREPARATION OF A CHIRAL TRIOL
    Publication number: 20240018076
    Abstract: The invention comprises a process for the preparation of a chiral triol of formula I wherein, R1 is hydrogen or halogen by way of an asymmetric hydrogenation of a ketone compound of formula IIa wherein, R1 is hydrogen or halogen and R2 is C1-6-alkyl; with hydrogen in the presence of an iridium spiro-pyridylamidophosphine catalyst (Ir-SpiroPAP catalyst). The chiral triols of formula I are versatile building blocks for the preparation of various pharmaceutically active drug substances such as for instance for statins.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 18, 2024
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Anna-Lena GLASS, Allen Yu HONG, Kurt PUENTENER
  • Processes for synthesis of substituted indole intermediates for the synthesis of serd compounds
    Patent number: 11873305
    Abstract: Provided herein are processes for the preparation of indolyl intermediates using Wenker Synthesis for the total synthesis of SERD compounds useful in the treatment of cancer.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 16, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Haiming Zhang, Jie Xu, Georg Wuitschik, Remy Angelaud, Sebastian Herold, Alfred Stutz, Tobias Bruetsch, Johannes Burkhard
  • Cysteine engineered antibodies and conjugates
    Patent number: 11873330
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: January 16, 2024
    Assignee: Genentech, Inc.
    Inventors: Sunil Bhakta, Jagath R. Junutula
  • METHODS FOR PREPARING MAMMALIAN CELLS FOR PERFUSION CELL CULTURE
    Publication number: 20240010709
    Abstract: Methods for preparing mammalian cells for perfusion cell culture processes that improve the growth and productivity of the cells are provided. Also provided are cell culture methods that involve subjecting mammalian cells to one or more perfusion procedures, which involve generating a solids phase and a liquid phase with a continuous flow centrifuge, and utilizing at least a portion of the solids phase to sustain, maintain and/or initiate a new cell culture. Perfusion bioreactor systems and components thereof are also provided.
    Type: Application
    Filed: May 25, 2023
    Publication date: January 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Ryan Christopher Hundley, Michael Wilson Laird, Jerome Joseph Bill, Christopher J. Dowd
  • PRODUCTION CELLS
    Publication number: 20240011066
    Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.
    Type: Application
    Filed: April 19, 2023
    Publication date: January 11, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Shahram Misaghi, Amy Shen, Inn Huam Yuk, Gavin Christian Barnard, Simon Auslaender, Niels Bauer, Benedikt Oswald
  • METHODS AND SYSTEMS FOR RAMAN SPECTRA-BASED IDENTIFICATION OF CHEMICAL COMPOUNDS
    Publication number: 20240011910
    Abstract: A method and System for identifying chemical compounds based on Raman spectroscopic measurements and in-silico simulated Raman spectra are disclosed. In various embodiments, Raman barcodes of an unknown chemical compound may be generated from Raman spectra obtained by performing Raman spectroscopic measurements on the unknown chemical compound. The Raman barcodes may then be compared with a library of reference in-silico simulated Raman barcodes of known chemical compounds and the identity of the unknown chemical compound may be determined based on the comparison.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 11, 2024
    Applicant: GENENTECH, INC.
    Inventors: Andrew James MAIER, Raphael FISH, Brendan Reed HUANG
  • ANTI-PDL1 ANTIBODY FORMULATIONS
    Publication number: 20240010732
    Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Ying YANG, Sreedhara ALAVATTAM
  • METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HERPESVIRUSES
    Publication number: 20240011017
    Abstract: Provided herein are methods of treating or preventing herpesvirus infection comprising modulating interactions between herpesvirus surface proteins and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
    Type: Application
    Filed: August 21, 2023
    Publication date: January 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Nadia MARTINEZ-MARTIN, Bushra HUSAIN
  • MULTIPLEXED TOTAL ANTIBODY AND ANTIBODY-CONJUGATED DRUG QUANTIFICATION ASSAY
    Publication number: 20240012003
    Abstract: Methods are disclosed to detect, characterize, measure, and quantify human and humanized antibodies, and their conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
    Type: Application
    Filed: September 19, 2023
    Publication date: January 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Surinder Kaur, Ola Saad, Manjui Violet Lee
  • Bispecific antigen-binding molecules and methods of use
    Patent number: 11866498
    Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Diego Ellerman, Teemu T. Junttila, Twyla Noelle Lombana, Dionysos Slaga, Christoph Spiess
  • Humanized anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 11866496
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: January 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng